Importance: Argon laser peripheral iridoplasty (ALPI) could be effective in widening residual angle closure following laser peripheral iridotomy (LPI).
INTRODUCTION
Primary angle-closure glaucoma (PACG) is potentially visually debilitating. The natural history of angle-closure glaucoma can be divided into three stages: primary angle-closure suspect (PACS), primary angle closure (PAC) and PACG. 1 Thomas et al. described 22% of untreated PACS patients progressing to PAC, and 28.5% of PAC patients developing PACG within 5 years. 2, 3 This suggests that persistent angle closure may lead to possible progression to angleclosure glaucoma.
Laser peripheral iridotomy (LPI), which relieves pupillary block, has long been the first-line treatment for PAC and PACG. [4] [5] [6] [7] [8] [9] However, it may not be successful in reversing angle closure in all cases because other mechanisms apart from or in addition to pupillary block may contribute to the angleclosure process. [10] [11] [12] [13] [14] In such situations, argon laser peripheral iridoplasty (ALPI) might have a role to reverse the appositional angle-closure process. ALPI involves the application of circumferential contraction laser burns to the far periphery of the iris. This results in immediate contraction of the peripheral iris stroma away from the drainage angle, thereby mechanically widening an appositionally closed angle.
The advent of anterior segment imaging has objectively enhanced our understanding as to the reason appositional angle closure persists despite a patent peripheral iridotomy. Other mechanisms identified in primary angle-closure eyes include plateau iris syndrome, [14] [15] [16] thick peripheral iris roll 16, 17 and large lens vault (LV).
17
Approximately 20-30% of PACS and PACG eyes continue to have appositional angle closure in the presence of a patent LPI. 15 The incidence of residual angle closure of at least one quadrant of iridotrabecular contact may be as high as 60%. 12 These eyes tend to have narrower angle opening distance (AOD) and increased iris thickness. 12 Persistence of appositional angle closure may lead to progression of the disease process, eventually requiring longterm medical treatment or surgical intervention. 18 When mechanisms of angle closure other than or in addition to pupillary block are present, ALPI may be effective in relieving residual appositional angle closure. 19, 20 In this study, we aimed to quantify changes in anterior segment parameters after ALPI using anterior segment optical coherence tomography (ASOCT) in eyes with residual non-acute angle closure and to examine the outcomes of these eyes following ALPI, in a predominantly Chinese population.
METHODS
This was a retrospective review of all PACS, PAC, PACG cases of phakic eyes, with visual acuity (VA) better than 6/12 (Snellen chart) and residual angle closure following LPI, which subsequently received ALPI, at the department of Ophthalmology, National University Hospital (NUH), Singapore. The records of all patients who underwent ALPI, within 3 months, following LPI for non-acute residual angle closure from January 2010 to February 2014 were obtained from the department's laser register. Cases with ASOCT images (Visante, Carl Zeiss Meditec, Dublin, CA, USA) a visit before and at least 2 weeks following ALPI were included in the study. Demographic data, diagnosis, ophthalmic data, ASOCT images and treatment outcomes were reviewed from medical records.
The study was approved by the hospital's institutional review board and was conducted in accordance with the principles of the Declaration of Helsinki.
PACS was defined as an eye in which the pigmented posterior trabecular meshwork was not visible on non-indentation gonioscopy for at least 180 in the primary position and the intraocular pressure (IOP) was ≤21 mmHg, in the absence of glaucomatous optic neuropathy or peripheral anterior synechiae (PAS). PAC was defined as eyes in which the posterior trabecular meshwork was not seen for ≥180 on non-indentation gonioscopy, with PAS and/or raised IOP (>21 mmHg) but without glaucomatous optic neuropathy. Glaucomatous optic neuropathy was defined as vertical cup-to-disc ratio ≥0.7, cup-to-disc ratio asymmetry >0.2 and/or focal notching with compatible visual field loss.
All ASOCT images before and after ALPI were analysed (range 0.5-5 years) using the Anterior Segment Analysis Program (National University Health System, Singapore). The methodology has previously been described. 17, 21 Only images with clearly discernible scleral spurs were selected for analysis by a single trained ophthalmologist (CZ). Vertical and horizontal ASOCT images were captured but only the horizontal images were analysed. The following angle and anterior chamber measurements were analysed: AOD 500 and AOD 750, trabecular iris surface area (TISA 500 and 750), anterior chamber width (ACW), anterior chamber volume (ACV), angle recess area (ARA), anterior chamber area (ACA), anterior chamber depth (ACD) and LV. The definitions for these parameters (Fig. 1) were also previously described. 17 Data was analysed using the Statistical Package for Social Sciences version 17.0 (SPSS Inc., Chicago, IL, USA). Comparison of mean values before and after ALPI was assessed using the paired t-test. The mean difference in parameter values before and after ALPI was also computed using linear regression with robust standard error to account for clustered data (correlation between eyes within subject). P value less than 0.05 was considered statistically significant. Sample size of 30 achieved more than 90% power to detect a 0.1 mm mean difference (standard deviation of 0.1) for AOD 500 before and after ALPI treatment, with a significance level (alpha) of 0.05 using a two-sided paired t-test.
RESULTS
ASOCT images were available for 62 eyes of 38 subjects before and after ALPI between January 2010 and February 2014. The ASOCT images from two eyes of two patients were excluded due to nonvisibility of the scleral spurs. All subjects had two or more quadrants of residual angle closure diagnosed gonioscopically in the presence of a patent peripheral iridotomy. We proceeded to analyse the remaining ASOCT images of 60 eyes of 36 patients. These comprised of 11 PACS eyes, 34 PAC eyes and 15 PACG eyes. The mean age of the patients was 63 AE 7.1 years. Most subjects were Chinese (83%) and women (75%) ( Table 1 ). The average laser settings were as follows: Power 250-400 mW, spot size 100-400 μm, duration 200 ms and average number of shots 32 AE 4. All eyes had vision better than 6/12 prior to receiving ALPI treatment.
Results from paired t-tests showed that ACV (89.8 vs. 102.3 mm Table 2 ). Statistically significant parameters identified were the same using linear regression accounting for within-subject correlation between eyes.
The mean follow-up duration was 2.1 years (range 0.5-5 years). During this time, there was no statistically significant difference in VA (0.09 AE 0.01 vs. 0.10 AE 0.01) after ALPI. Three eyes demonstrated a 1-1.5 line decrease in Snellen VA. There was no evidence of clinical corneal decompensation, nor was there a need for additional IOP lowering drops compared to before ALPI (24 of 60 eyes were receiving IOP lowering medications at the time of ALPI) and before all further surgical interventions. Five PACG eyes underwent combined cataract extraction and glaucoma filtration surgery. All but one eye had Snellen VA 6/9 at the time of surgery. One eye had Snellen VA of 6/12 (1 line drop) at the time of combined surgery. The mean time to surgery was 10 months (range 5-19 months). Two eyes (one PAC and one PACS) underwent cataract surgery. Snellen VA was 6/9 at the time of cataract surgery, with a mean time to surgery of 20.5 months (Table 3) .
DISCUSSION
Conventional ALPI treatment involves the placement of approximately 24 laser burns, of large spot size (up to 500 μm), at low power (240-400 mW) and long duration (up to 700 ms) over 360 , spaced two spot diameters apart. In our centre, our ALPI premedication regime consisted of administration of two drops of 2% pilocarpine given 5 min apart and Figure 1 . Schematic illustration of the anterior chamber and anterior chamber angle parameters. ACD, anterior chamber depth; ACW, anterior chamber width; AOD 500, angle opening distance measured at 500 μm from the scleral spur; ARA 500, angle recess area measured at 500 μm from the scleral spur; LV, lens vault; TISA 500/750, trabecular-iris space area measured at 500/750 μm from the scleral spur. one drop of brimonidine 15 min prior to the procedure to blunt any post-procedural IOP spike.
ALPI was performed following administration of topical anaesthesia, using an Abraham iridotomy contact lens. All patients were administered topical steroids for four times a day over a duration of 2 weeks following ALPI.
Histopathological findings suggest that collagen heat shrinkage results in the short-term effect seen following ALPI, while the contraction of a fibroblastic membrane in the areas of laser application are responsible for the long-term effects. 22 Laser iridoplasty can also be performed using diode 23, 24 and Nd:YAG lasers. 25 Although the role of ALPI was better established in acute primary angle-closure attacks, its role in non-acute angle closure is less well-defined. 23, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] ALPI in eyes with plateau iris configuration is well established in the literature. In addition, eyes with plateau iris syndrome treated with ALPI have shown good long-term success with low recurrence of appositional closure and need for retreatment. 36 Various studies have demonstrated the IOP lowering effects of ALPI in PAC and PACG. Chew et al. 20 described the additional IOP lowering effects of ALPI in a case series of chronic angle-closure glaucoma on maximally tolerated medical treatment. Similarly, in a randomized controlled trial of angle closure and angle-closure glaucoma eyes, Narayanaswamy et al. 37 demonstrated that ALPI can reduce IOP when used as an adjunct to medical therapy. The ideal timing of ALPI in achieving the most optimum outcomes remains controversial as mixed results have been reported even in plateau iris syndrome, where the indication of ALPI in a non-acute angle-closure setting was earliest described. Ritch et al. concluded that variable results observed might possibly be due to the severity of the angle closure or angle-closure glaucoma at the time of ALPI intervention. 36, 38 Although our findings suggest a possible role for ALPI in PACS eyes with persistent appositional angle closure following LPI, long-term randomized controlled trials are needed to determine the risk of progression of PACS eyes with persistent angle closure, ALPI can be performed in the outpatient setting and was demonstrated in our retrospective series to have a good clinical safety profile; this is consistent with results from other studies. 36, 37 In this study, theoretical concerns of clinical corneal decompensation (refractory corneal oedema) or rapid progression of cataracts were not observed. Mild iritis is often seen post-laser. A longer course of topical steroids, over 10 days to 2 weeks, is recommended because there is more inflammation in comparison to LPI. This may manifest as a symptom of discomfort in the absence of cells or flare on clinical examination. In our series, none of the patients demonstrated protracted inflammation post-ALPI following a 2-week course of topical steroids administered four times a day.
The absence of statistically significant changes to ACW, ACD, ACA and LV is consistent with placement of the ALPI burns peripherally whereby ALPI *P-value from paired t-test. † Linear regression with robust standard error to account for clustered data (subjects with both eyes data). ACA, anterior chamber area; ACD, anterior chamber depth; ACV, anterior chamber volume; ACW, anterior chamber width; AOD, angle opening distance; ARA, angle recess area; CI, confidence interval; IOP, intraocular pressure; SE, standard error; TISA, trabecular iris surface area. effects changes predominantly in the angles. Studies have previously described increased iris thickness 12, 17 in association with angle-closure eyes and eyes with residual angle closure following LPI. Our results demonstrated an increase in AOD and ARA, which are objective measures of widened angles following ALPI. An increase in TISA 500 and 750 suggest thinning of the peripheral iris following ALPI, further resulting in an increase in AOD and ARA. Our findings of an increase in TISA 500 and 750 corroborate with the findings of Liu et al., 39 who described significant cross-sectional thinning of the iris at laser-treated areas in comparison with untreated areas. Our findings support the twofold effects of ALPI at the angle, which in addition to contracting the iris stroma and pulling the iris away from the angle relieving appositional iridotrabecular contact, ALPI acts to thin the iris tissue at the crowded angle, hence increasing the TISA. These findings reinforce the importance of aiming the ALPI shots at the far peripheral iris for maximal effect. TISA 750 was also described to demonstrate high level of efficiency in discriminating narrow from open angles. 40 ALPI resulted in an overall statistically significant increase in ACV. The clinical significance of this has to be further examined.
The permanence of ALPI's effects on appositional angle closure along with its effects on angle parameters, studied objectively through angle morphology on ASOCT, and its role in retarding further evolution of PACS eyes into PAC or PACG remains a question to be answered. Prospective studies are required to assess the permanence of ALPI's effects to angle structures over time.
Although the success of ALPI as a treatment modality is well established in APAC with welldesigned randomized controlled trials, the level of evidence of its use in non-acute angle-closure eyes is limited. 41 As our understanding of angle-closure mechanisms increases with the advent of ASOCT, more mechanisms such as peripheral iris crowding, 17 aside from pupil block and plateau iris syndrome, have been described. Whether ALPI has a role to play in modifying specific angle parameters in described selected mechanisms aside from plateau iris configuration, to delay progression of the angle-closure processes is not known. Future prospective studies will be needed to establish this relationship.
Our results should be interpreted with a view of the limitations inherent in a retrospective study. The ALPI laser parameters were not standardized prospectively, as lasers were performed by different Ophthalmologists over a range of settings variation. Nonetheless, in spite of these variations, the outcomes following ALPI for residual angle closure in this retrospective case series appear promising. In our centre, ALPI is offered electively only to patients with ≥180 of appositional angle closure, following LPI, for eyes with non-acute angle closure. Ultrasound biomicroscopy was not performed in all cases. Ultrasound biomicroscopy is important in distinguishing between plateau iris syndrome versus non-plateau iris mechanisms, as the role of ALPI in plateau iris syndrome has been well established in previous case series. 36 However, the presence of a clinically documented double hump sign on indentation gonioscopy would be similarly diagnostic. Our study was not powered to allow for subanalysis of various mechanisms of angle closure previously described. 17 With a wide follow-up range (0.5-5 years), the possibility of parameter change over time will be difficult to establish in this retrospective series; hence, prospective studies are recommended to evaluate the effects of ALPI on the angle over time. The authors do also recognize the limitation in the use of ASOCT imaging as an objective tool in assessing for changes to angle parameters. A single trained ophthalmologist (ZC) analysed the images; hence, there was a possibility for bias in the interpretation of the data. For eyes diagnosed with PAC and PACG, in which PAS might be present, results might be biased towards minimal effect if the PAS was in the area of the scan and the reverse could occur in the absence of PAS. Vertical images were omitted from analysis for various reasons. Inadvertent variable pressure on the upper lid during imaging might result in artificial widening of the superior angles. Angle parameters, especially the sclera spur, were better identified on horizontal images. Hence, horizontal images were selectively analysed in our study. Only eyes with well-defined scleral spurs on ASOCT images were analysed.
In conclusion, this study adds to current body of evidence that ALPI can result in changes to the angle morphology in eyes with residual angle closure following LPI. We have demonstrated a reasonable clinical safety profile (no clinical corneal decompensation) and IOP response, in a predominantly Chinese population with comprehensive long-term analysis (mean follow-up duration 2.1 years).
